인투셀

287840KOSDAQ자연과학 및 공학 연구개발업

44.3 / 100

Reference Date: 2026-07-24

Financial Score7.5 / 40

News Sentiment18.8 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Slightly down 3.5% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

IntuCell is an ADC platform technology company specializing in linker and drug development, leveraging its OHPAS linker and PMT platform technologies to enhance drug delivery efficiency and selectivity. The company utilizes proprietary drug technologies such as Duocarmycin and Nexatecan to establish a competitive edge in oncology, with a pipeline including the B7-H3-targeting ADC candidate ITC-6146RO.

Number of Employees

—

Average Salary

—

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 43.644.0Point

PBR

14.20Industry Average 2.520.0Point

5.6x industry avg (risky)

ROE

-65.72Industry Average -32.093.5Point

2.0x industry avg (excellent)

Debt Ratio

53.66Industry Average 7.310.0Point

7.3x industry avg (risky)

Trend 2024~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼20.9% (1-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼5.2% (1-year basis)

ROE Trend

0.0 / 4

Avg ROE -80.6% (improving, 2yr)

Detailed News Sentiment

8 totalPositive 6Neutral 2Negative 0Average Sentiment Score 75

Positive
인투셀, 삼성에피스 본계약 소식에…주가 12%대 상승세 [Why 바이오...
인투셀의 주가가 삼성바이오에피스와의 본계약 체결 소식으로 인해 크게 상승했다.
Positive
삼성바이오에피스-인투셀, ADC 신약 공동개발 본계약 체결
삼성바이오에피스와 인투셀의 ADC 신약 공동개발 계약 체결로 인투셀의 기술 가치 상승 기대.
Positive
삼성바이오에피스, 인투셀과 항암 ADC 신약 'SBE303' 상업화 ...
삼성바이오에피스와 인투셀의 ADC 신약 공동개발 계약 체결로 인투셀의 임상 진행 기대감 상승.

Detailed Momentum

52-week position1.0Point

Near 52w low (7%, downtrend)

Current 23,400Won52-week high 71,00052-week low 19,770

1-month return2.0Point

1m -3.51% (slight drop)

Volume trend5.0Point

Volume flat

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral투자판단관련주요경영사항 (Nectin-4 단백질 표적 고형암 치료제 후보물질 SBE303에 대한 ADC 플랫폼기술 이전계약 체결)2026-07-22